Company news
Zymeworks Inc. news in 2021
Zymeworks Inc.'s news releases, calls and decks from 2021, newest first.
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
December 8, 2021
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
November 30, 2021
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
November 18, 2021
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer
November 8, 2021
Zymeworks Reports 2021 Third Quarter Financial Results
November 2, 2021
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
October 25, 2021
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
October 4, 2021
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
September 11, 2021
Zymeworks Reports 2021 Second Quarter Financial Results
August 3, 2021
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms
August 2, 2021
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy
July 27, 2021
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
May 5, 2021
Zymeworks Reports 2021 First Quarter Financial Results
May 4, 2021
Zymeworks Announces Succession Plan for Chief Medical Officer
April 18, 2021
Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
March 9, 2021
Zymeworks Reports 2020 Year-End Financial Results
February 23, 2021
Zymeworks Expands Commercial Team and Creates New R&D Role
February 8, 2021
Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development
January 26, 2021
Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium
January 14, 2021
Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities
January 10, 2021